Trimodal therapy may be an effective alternative to radical cystectomy for recurrent, high-grade T1 bladder cancer, according to a study published in the Journal of Clinical Oncology.

Adding PD-(L)1 inhibitors to chemotherapy improved outcomes, but PD-(L)1 inhibitors alone were no more effective than chemotherapy alone in patients with gastric, gastroesophageal junction, and ...

Americans have the worst health care among the world’s wealthy nations, according to a report from health care think-tank The Commonwealth Fund. The report showed that people in the United States die ...

Treatment with ¹⁷⁷Lu-PSMA-617 appears more effective than changing ARPIs for patients with mCRPC whose disease progressed on a prior ARPI.

(HealthDay News) — Axatilimab produces responses in patients with recurrent or refractory graft-vs-host disease (GVHD), according to a study published in The New England Journal of Medicine.

SBRT and hypofractionated CRT produced similar outcomes in patients with inoperable stage I NSCLC in a phase 3 trial.

A large study suggests that pediatric cancer patients are more likely to die in the hospital than at home. The data showed that 52% of patients died in the hospital, and 40% died at home. These ...

The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.

Implementing weighted-average drug pricing in the United States could reduce the cost of cancer drugs, data suggest.

A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.

Perioperative pembrolizumab can improve OS when combined with neoadjuvant chemotherapy in patients with high risk, ...

The FDA has approved Rybrevant (amivantamab) in combination with chemotherapy to treat advanced, EGFR-mutant NSCLC that progressed on or after treatment with an EGFR TKI.